NASDAQ · NVS
Healthcare · Drug Manufacturers - General
$140.37
Down-$0.55 (-0.39%)
Updated Sep 20, 2026, 10:36 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NVS closed at $140.37 after 19 trading sessions, down 11.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $140.87 | $141.15 | $139.60 | $140.37 | 2.25M |
| Sep 17, 2026 | $140.12 | $141.21 | $139.97 | $140.92 | 1.71M |
| Sep 16, 2026 | $140.58 | $141.46 | $138.28 | $138.70 | 1.89M |
| Sep 15, 2026 | $138.76 | $139.11 | $137.37 | $138.62 | 2.37M |
| Sep 14, 2026 | $141.64 | $141.64 | $138.99 | $138.99 | 2.48M |
| Sep 11, 2026 | $139.31 | $139.55 | $137.00 | $137.16 | 2.35M |
| Sep 10, 2026 | $138.76 | $139.43 | $137.46 | $137.48 | 2.42M |
| Sep 9, 2026 | $138.14 | $139.45 | $137.30 | $137.48 | 2.94M |
| Sep 8, 2026 | $139.94 | $140.46 | $137.115 | $137.70 | 10.27M |
| Sep 4, 2026 | $159.90 | $160.93 | $159.625 | $159.99 | 1.29M |
| Sep 3, 2026 | $164.48 | $164.48 | $161.42 | $163.09 | 2.45M |
| Sep 2, 2026 | $160.80 | $163.18 | $160.38 | $162.46 | 4.34M |
| Sep 1, 2026 | $162.15 | $163.57 | $160.21 | $161.25 | 4.33M |
| Aug 31, 2026 | $152.60 | $152.74 | $151.685 | $152.06 | 1.29M |
| Aug 28, 2026 | $154.51 | $154.565 | $152.77 | $153.81 | 1.17M |
| Aug 27, 2026 | $155.925 | $155.93 | $154.43 | $154.65 | 1.22M |
| Aug 26, 2026 | $158.41 | $159.19 | $157.44 | $157.54 | 1.47M |
| Aug 25, 2026 | $158.51 | $160.29 | $157.83 | $159.98 | 998.18K |
| Aug 24, 2026 | $157.12 | $158.46 | $156.77 | $158.02 | 801.26K |
The latest Smart Investors Daily articles mentioning NVS.
NVS research
Company profile and research snapshot.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 9, 2026 | ARGUS RESEARCH CORPORATION | Buy | — |
| Jun 30, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
WINNIPEG, MB / ACCESS Newswire / September 18, 2026 / (GSS-TSX.V)(GSR-Frankfurt/Freiverkehr & Xetra) (the "Company" or "Gossan") is pleased to announce that the Board of Directors has appointed Kevin Norberg as interim Chief Executive Officer and Director, effective September 18, 2026.
Yahoo · Sep 18, 2026
The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption, while therapeutic agents and radiotheranostics are key growth segments. North America holds the largest market share, with Asia-Pacific forecast to grow fastest. The report analyses market trends, technologies, applications, regional opportunities and leading companies, in
Yahoo · Sep 18, 2026
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of
Benzinga · Sep 18, 2026
https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000326984_en.pdf
Interpretive context generated from the platform’s current data sources.
Novartis AG shares have experienced notable downward pressure in recent weeks, trading at $140.37, which represents a 12.44% decline over the past month, per SID market data. Over a three-month horizon, the stock has retreated 4.56%, though it maintains a positive 14.33% return on a trailing twelve-month basis. The current price sits well below both the 50-day moving average of $152.45 and the 200-day moving average of $150.04, indicating sustained bearish technical momentum. The 14-day relative strength index registers at 34.6, approaching oversold territory and suggesting intensified selling activity. Novartis carries a beta of 0.438, per Massive/Polygon data, reflecting significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 1.65 million shares. The company's market capitalization currently totals approximately $259 billion, positioning it among the largest global pharmaceutical firms by market value.
Novartis AG currently trades at a price-to-earnings ratio of 18.18, according to SID market data, positioning it within a moderate valuation range for the healthcare sector. The company's price-to-book ratio stands at 5.90, reflecting a significant premium to book value that is consistent with large-cap pharmaceutical companies possessing substantial intangible asset portfolios. The PEG ratio registers at negative 0.79, per SEC filings, which limits its utility as a growth-adjusted valuation metric in the current context. Novartis offers a dividend yield of 3.31%, providing income-oriented investors with a yield meaningfully above the broader market average. This yield level is noteworthy given the recent price decline, as the lower share price has mechanically elevated the yield percentage. Within the healthcare sector, Novartis's combination of a sub-20 P/E ratio and above-average dividend yield positions the stock as a value-oriented large-cap pharmaceutical holding based on current fundamental metrics.
Novartis AG registers a composite smart money score of 58 out of 100, generating a neutral overall signal, per SID market data. Institutional activity represents the strongest component, scoring 21.0 out of 25, indicating robust engagement from large fund managers and asset allocators in the stock. Insider activity scores 12.5 out of 25, reflecting a moderate level of transactions by company executives and board members, according to SEC Form 4 filings. Dark pool trading activity registers at 12.0 out of 25, suggesting average levels of off-exchange institutional block trading. Congressional trading interest scores 12 out of 25, indicating limited but present activity among disclosed legislative portfolios. The divergence between the elevated institutional score and more muted readings across insider, dark pool, and congressional categories contributes to the overall neutral composite signal. Institutional holders appear to maintain significant positions based on 13F institutional filings, though other smart money indicators do not confirm directional conviction at current price levels.
Novartis AG reported first-quarter earnings per share of $2.41, exceeding the consensus analyst estimate of $2.16 by $0.25, representing an 11.6% positive surprise, according to company earnings reports. This followed a fourth-quarter result of $1.99 per share, which fell short of the $2.07 estimate by $0.08, marking a modest negative surprise. Looking ahead, analyst estimates project earnings of $2.10 per share for the upcoming quarter with results expected on May 1, 2026, and $2.13 per share for the following quarter scheduled for July 16, 2026. The sequential earnings trajectory from analyst estimates suggests anticipated growth from Q4's $1.99 through Q1's $2.41 actual result. The company's next scheduled earnings release on April 28, 2026, will provide further visibility into whether Novartis can sustain the positive momentum demonstrated by its most recent quarterly beat and maintain its earnings trajectory through the remainder of the fiscal year.
Wall Street analyst sentiment on Novartis AG reflects a divided outlook based on recent rating activity, per SID consensus data. On July 14, 2026, TD Cowen reiterated a Hold rating, while Berenberg maintained its Hold stance on July 13. On the same date, Rothschild & Co Redburn reiterated a Sell rating, representing the most bearish position among recent coverage. Countering this cautious tone, Argus Research Corporation upgraded NVS to Buy from Hold on July 9, 2026, the only directional change among the five most recent ratings. Intesa Sanpaolo Equity Research maintained a Buy rating on June 30, 2026, according to Wall Street analyst reports. Among these five recent actions, the distribution shows two Buy ratings, two Hold ratings, and one Sell rating, producing a balanced consensus. The predominance of rating reiterations rather than changes suggests that most covering analysts have not altered their fundamental thesis despite the stock's 12.44% monthly decline.
The latest Smart Investors Daily articles mentioning NVS.
